[{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Noveome Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"TheiaLife","sponsor":"LifeSci Consulting","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.A.E","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"7-Methylxanthine","moa":"Adenosine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TheiaLife","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TheiaLife \/ LifeSci Consulting","highestDevelopmentStatusID":"8","companyTruncated":"TheiaLife \/ LifeSci Consulting"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Visus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Visus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Visus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Visus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Ophthalmics \/ Bausch Health"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors||VEGF\/PDGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Guggenheim Securities"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"angiogenesis inhibitors","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Science \/ EyePoint Pharmaceuticals"},{"orgOrder":0,"company":"Greater Houston Retina Research","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Faricimab","moa":"Angiopoietin-2 | Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Greater Houston Retina Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Greater Houston Retina Research \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Greater Houston Retina Research \/ Genentech"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Lexitas"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Galimedix Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"GAL-101","moa":"APP","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Galimedix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galimedix Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Galimedix Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Hong Kong Polytechnic University","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"HONG KONG","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hong Kong Polytechnic University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hong Kong Polytechnic University \/ Alcon Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hong Kong Polytechnic University \/ Alcon Inc"},{"orgOrder":0,"company":"Hovione","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PORTUGAL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hovione \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Unity Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascentage Pharma \/ Unity Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Unity Biotechnology"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"||BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Foselutoclax","moa":"BCL-XL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Betaliq","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BTQ-1901-A","moa":"Beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betaliq \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Undisclosed"},{"orgOrder":0,"company":"Betaliq","sponsor":"Trial Runners, LLC | Summit Analytical LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nebivolol","moa":"Beta-2 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Betaliq","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betaliq \/ Trial Runners, LLC | Summit Analytical LLC","highestDevelopmentStatusID":"8","companyTruncated":"Betaliq \/ Trial Runners, LLC | Summit Analytical LLC"},{"orgOrder":0,"company":"Invirsa","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Invirsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Undisclosed"},{"orgOrder":0,"company":"Invirsa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Undisclosed"},{"orgOrder":0,"company":"Invirsa","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor||p53\/Pax6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Invirsa","sponsor":"Cincytech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Invirsa \/ Cincytech","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ Cincytech"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Telios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Choline","moa":"BTK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Telios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Telios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"SBI-100","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Skye Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CCR receptor antagonists","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AAVCAGsCD59","moa":"CD59","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemera Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"OK-101","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Ora, Inc"},{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"Chemokine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eurobio Scientific","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Eurobio Scientific \/ Allergan Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Eurobio Scientific \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TP-03","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TP-03","moa":"Chloride channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Freedom Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Freedom Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Freedom Capital Markets"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Funding","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Tufts Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Tufts Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Tufts Medical Center"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ AmbioPharm","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ AmbioPharm"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"OKYO Pharma","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Public Offering","leadProduct":"Urcosimod","moa":"CMKLR1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OKYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OKYO Pharma \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"OKYO Pharma \/ Thinkequity"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"ForSeeCon Eye Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"ABV-1701","moa":"Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ ForSeeCon Eye Corporation","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ ForSeeCon Eye Corporation"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABV-1701","moa":"||Collagen synthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Expanded Collaboration","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.20999999999999999,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NGM621","moa":"Complement C3 (CO3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NGM Biopharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Avacincaptad Pegol","moa":"Complement C5 (CO5)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IVERIC bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IVERIC bio \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Iptacopan Hydrochloride","moa":"Complement factor B","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Danicopan","moa":"Complement factor D","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"GEM103","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Fs Development Corp","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Recombinant Human Complement Factor H","moa":"Complement Factor H","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.22,"dosageForm":"Injection","sponsorNew":"Gemini Therapeutics \/ Fs Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"Gemini Therapeutics \/ Fs Development Corp"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Public Offering","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.5,"dosageForm":"Injection","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVD-104","moa":"Complement pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aviceda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aviceda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aviceda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"L.V. Prasad Eye Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nepafenac","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"L.V. Prasad Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"L.V. Prasad Eye Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"L.V. Prasad Eye Institute \/ Allergan"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Topotecan Hydrochloride","moa":"DNA topoisomerase I, mitochondrial","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Apexian Pharmaceuticals","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apexian Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apexian Pharmaceuticals \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Apexian Pharmaceuticals \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opus Genetics \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Ocuphire Pharma"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APX3330","moa":"DNA-(apurinic or apyrimidinic site) lyase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Opus Genetics \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Carotuximab","moa":"Endoglin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Curacle","sponsor":"Th\u00e9a Open Innovation, France","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CU06-1004","moa":"Endothelial cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Curacle \/ Th\u00e9a Open Innovation, France","highestDevelopmentStatusID":"8","companyTruncated":"Curacle \/ Th\u00e9a Open Innovation, France"},{"orgOrder":0,"company":"Curacle","sponsor":"KCRN Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CU06-1004","moa":"Endothelial cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curacle","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Curacle \/ KCRN Research","highestDevelopmentStatusID":"8","companyTruncated":"Curacle \/ KCRN Research"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Perfuse Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PER-001","moa":"Endothelin pathway","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Perfuse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Perfuse Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perfuse Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Bios Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Bios Partners","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Bios Partners"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ONL Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"ONL1204","moa":"Fas","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ONL Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"ONL Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ONL Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Hatteras Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Hatteras Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Hatteras Venture Partners"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TTHX1114","moa":"FGF1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trefoil Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RBM-007","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Aju Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Aju Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Aju Pharma"},{"orgOrder":0,"company":"Ribomic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Undisclosed"},{"orgOrder":0,"company":"Ribomic","sponsor":"Midwest Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ribomic \/ Midwest Eye Institute","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Midwest Eye Institute"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Udonitrectag","moa":"FGFR4","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Recordati Rare Diseases \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Recordati Rare Diseases \/ Syneos Health"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"LL-BMT1","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"IUVO","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"PA5108","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ IUVO","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ IUVO"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"D-4517.2","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"D-4517.2","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2023","type":"Inapplicable","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"||FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Tribe Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Carbohydrate","year":"2025","type":"Series B Financing","leadProduct":"Hydroxyl Dendrimer","moa":"FX receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Ashvattha Therapeutics \/ Tribe Capital","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha Therapeutics \/ Tribe Capital"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RG7774","moa":"FXR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"GDNFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroptika \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Undisclosed"},{"orgOrder":0,"company":"Neuroptika","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NRO-1","moa":"GDNFR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroptika \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"SURF-201","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Oncology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Undisclosed"},{"orgOrder":0,"company":"iDrop","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NORWAY","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iDrop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"iDrop \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iDrop \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Forbion"},{"orgOrder":0,"company":"Oxular","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2025","type":"Acquisition","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Series A Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ripple Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eclipse Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eclipse Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ OcuMension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"NCX 4251","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nicox Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nicox Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Quan Dong Nguyen","sponsor":"Global Ophthalmic Research Center (GORC) | Oculis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"OCS-01","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Quan Dong Nguyen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Quan Dong Nguyen \/ Global Ophthalmic Research Center (GORC) | Oculis","highestDevelopmentStatusID":"8","companyTruncated":"Quan Dong Nguyen \/ Global Ophthalmic Research Center (GORC) | Oculis"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"OTX-DED","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Ocular Therapeutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"OXU-001","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Oxular \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Undisclosed"},{"orgOrder":0,"company":"Oxular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxular","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxular \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxular \/ Undisclosed"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST-100","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stuart Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Stuart Therapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Galegenimab","moa":"HTRA1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Anastasia Vishnevetsky, MD, MPH","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod Alfa","moa":"IgG receptor FcRn large subunit p51","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Anastasia Vishnevetsky, MD, MPH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anastasia Vishnevetsky, MD, MPH \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Anastasia Vishnevetsky, MD, MPH \/ Argenx"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vamikibart","moa":"IL6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vamikibart","moa":"IL6","graph1":"Ophthalmology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Sanhuangjingshimingwan","moa":"Immune","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Silk Technologies, Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SDP-4","moa":"immunomodulators","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Silk Technologies, Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Silk Technologies, Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Silk Technologies, Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Belfast Health and Social Care Trust","sponsor":"Araim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Belfast Health and Social Care Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Araim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Surface Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolic Acid","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Surface Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Surface Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Surface Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OTT166","moa":"Integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Parexel"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Integrin (ITG)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Kreos Capital"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Acelyrin","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ AyurMaya","highestDevelopmentStatusID":"8","companyTruncated":"Acelyrin \/ AyurMaya"},{"orgOrder":0,"company":"Andover Eye Associates","sponsor":"Statistics & Data Corporation | Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Andover Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andover Eye Associates \/ Statistics & Data Corporation | Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Andover Eye Associates \/ Statistics & Data Corporation | Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"||KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Canaan Partners"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS-111","moa":"KATP channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"UNR844","moa":"Lens protein disulfide bonds","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Curatis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Undisclosed"},{"orgOrder":0,"company":"Curatis","sponsor":"Great Health Companion Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Great Health Companion Group","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Great Health Companion Group"},{"orgOrder":0,"company":"Curatis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pamapimod","moa":"||MAP kinase p38 alpha","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Curatis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curatis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Curatis \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Palatin Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Palatin Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Palatin Technologies"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Pharmaxis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BI 1467335","moa":"Membrane copper amine oxidase (AOC3)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Pharmaxis","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Pharmaxis"},{"orgOrder":0,"company":"Hemera Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"HMR59","moa":"Membrane inhibitor of reactive lysis (CD59)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hemera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hemera Biosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dipraglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Addex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Addex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Wagner Macula & Retina Center","sponsor":"Oxurion","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Wagner Macula & Retina Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wagner Macula & Retina Center \/ Oxurion","highestDevelopmentStatusID":"8","companyTruncated":"Wagner Macula & Retina Center \/ Oxurion"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Avania","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Avania","highestDevelopmentStatusID":"8","companyTruncated":"Azura Ophthalmics \/ Avania"},{"orgOrder":0,"company":"Beijing Anlong Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AL-001","moa":"monoclonal antibodies: neural","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Beijing Anlong Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Anlong Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Anlong Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Anlong Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AL-001","moa":"monoclonal antibodies: neural","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Beijing Anlong Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Anlong Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Anlong Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Glaukos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glaukos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glaukos \/ Undisclosed"},{"orgOrder":0,"company":"Glaukos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glaukos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Glaukos \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AGN-190584","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oyster Point Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Oyster Point Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oyster Point Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACT-01","moa":"Neurotrophic factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accure Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Nerve Growth Factor","moa":"Neurotrophic tyrosine kinase receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Aperta Biosciences, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aperta Biosciences, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aperta Biosciences, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aperta Biosciences, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Financing","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stealth Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stealth Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BI1584862","moa":"Phospholipid","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"Rezolute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RZ402","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rezolute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/ Undisclosed"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.76000000000000001,"dosageForm":"Injection","sponsorNew":"KalVista Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bicycle Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Bank Degroof Petercam"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"Plasma kallikrein (KLKB1)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ VIB"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"QLS-101","moa":"Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"QLS-101","moa":"||Potassium channel","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Qlaris Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio \/ Undisclosed"},{"orgOrder":0,"company":"Fondazione Policlinico Universitario Agostino Gemelli","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Cord Blood Cell","moa":"Progenitor cell","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Fondazione Policlinico Universitario Agostino Gemelli","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Policlinico Universitario Agostino Gemelli \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"8","companyTruncated":"Fondazione Policlinico Universitario Agostino Gemelli \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"SIFI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SIFI \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SIFI \/ Undisclosed"},{"orgOrder":0,"company":"Signal 12","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Signal 12","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Signal 12 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Signal 12 \/ Undisclosed"},{"orgOrder":0,"company":"Pharmadax","sponsor":"Glia","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Pharmadax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharmadax \/ Glia","highestDevelopmentStatusID":"8","companyTruncated":"Pharmadax \/ Glia"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sepetaprost","moa":"Prostanoid EP3 receptor | Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EyePoint Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyePoint Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"PolyActiva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"KALA Bio \/ SR One Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One Capital Management"},{"orgOrder":0,"company":"KALA Bio","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KALA Bio","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"KALA Bio \/ SR One Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"KALA Bio \/ SR One Capital Management"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2022","type":"Private Placement","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Kala Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"KPI-012","moa":"Protease","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kala Pharmaceuticals \/ Kala Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kala Pharmaceuticals \/ Kala Pharmaceuticals"},{"orgOrder":0,"company":"Okogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"OKG-0301","moa":"Protein Biosynthesis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Okogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Okogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Okogen \/ Undisclosed"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diquafosol Sodium","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RCI001","moa":"RAC1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"||Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Razuprotafib","moa":"Receptor-type tyrosine-protein phosphatase beta","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AURN001","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AURN001","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurion Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurion Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ABBV-RGX-314","moa":"RNA","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Regenxbio"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"VivaVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VVN539","moa":"ROCK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"VivaVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"VivaVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VivaVision \/ Undisclosed"},{"orgOrder":0,"company":"D. Western Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"H-1337","moa":"ROCK\/AKT\/PDK1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"D. Western Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"D. Western Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D. Western Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"D. Western Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"H-1337","moa":"ROCK\/AKT\/PDK1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"D. Western Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"D. Western Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"D. Western Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Valo Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OPL-0401","moa":"ROCK1\/2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Valo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valo Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valo Health \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI 764524","moa":"Semaphorin-3A (SEMA3A)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Neurotrials","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oculis \/ Neurotrials","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Neurotrials"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Oculis \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BofA Securities"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Privosegtor","moa":"SGK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"TMEM97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CT1812","moa":"Sigma intracellular receptor 2 (TMEM97)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CT1812","moa":"Sigma intracellular receptor 2 (TMEM97)","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cognition Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Runcaciguat","moa":"Soluble guanylate cyclase","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YD Life Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Undisclosed"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IC265","moa":"Syk","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IACTA Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DT-168","moa":"TCF4 gene expression","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Design Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Design Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DT-168","moa":"TCF4 gene expression","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Design Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Design Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oculis \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Ora, Inc"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"Oculis","sponsor":"BBA\/\/Fjeldco","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Financing","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Suspension","sponsorNew":"Oculis \/ BBA\/\/Fjeldco","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ BBA\/\/Fjeldco"},{"orgOrder":0,"company":"Oculis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Oculis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ Undisclosed"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Oculis","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AGC Biologics \/ Oculis","highestDevelopmentStatusID":"8","companyTruncated":"AGC Biologics \/ Oculis"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"EYS606","moa":"TNF-alpha receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eyevensys","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Eyevensys \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Eyevensys \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roivant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"601","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Dompe Farmaceutici","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Aramis Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"A197","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aramis Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Aramis Biosciences \/ Safar Partners","highestDevelopmentStatusID":"8","companyTruncated":"Aramis Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ADX-038","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ADARx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allgenesis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Lexitas"},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Allgenesis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AffaMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AffaMed Therapeutics \/ Allgenesis Biotherapeutics"},{"orgOrder":0,"company":"Amydis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AMDX-2011P","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amydis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amydis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amydis \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Annexin A5","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Annexin Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Annexin Pharmaceuticals","sponsor":"InFocus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ANXV","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Annexin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annexin Pharmaceuticals \/ InFocus Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Annexin Pharmaceuticals \/ InFocus Clinical Research"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AR-17043","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"AxeroVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AXR-270","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AxeroVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AxeroVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AxeroVision \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BI 1584862","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BI1815368","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI764524","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI764524","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI771716","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"BRIM Biotechnology Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"BRM424","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"BRIM Biotechnology Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BRIM Biotechnology Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRIM Biotechnology Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Biotheravision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BTV100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Biotheravision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biotheravision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotheravision \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CBT-004","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CBT-006","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CBT-008","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cloudbreak Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cloudbreak Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cloudbreak Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EyebioKorea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EB-203","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EyebioKorea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EyebioKorea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EyebioKorea \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ECF843","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EG017","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Evergreen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"EG-301","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Evergreen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Evergreen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evergreen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EnnovaBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ENN0403","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"EnnovaBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EnnovaBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnnovaBio \/ Undisclosed"},{"orgOrder":0,"company":"GL Pharm Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GLH8NDE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"GL Pharm Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GL Pharm Tech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GL Pharm Tech \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Human Amniotic Membrane","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Iolyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ILYX-002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Iolyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Iolyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Iolyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intratus","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"INT-11P001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Intratus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intratus \/ Glaukos","highestDevelopmentStatusID":"8","companyTruncated":"Intratus \/ Glaukos"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iView Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IVW-1001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"iView Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"iView Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iView Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-81201887","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JNJ-81201887","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Research Institute, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"K-321","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kowa Research Institute, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kowa Research Institute, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Research Institute, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KIO-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KIO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KIO-201","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiora Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Amber Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Lufepirsen","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Amber Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amber Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amber Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Innostellar Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LX102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innostellar Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innostellar Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innostellar Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innostellar Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LX102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innostellar Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innostellar Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innostellar Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theratocular Biotek Co.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MG-O-1002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Theratocular Biotek Co.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Theratocular Biotek Co. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theratocular Biotek Co. \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Novelia","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OT202","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuMension Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QA102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QA102","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"Smilebiotek Zhuhai Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QA108","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Smilebiotek Zhuhai Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Smilebiotek Zhuhai Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Smilebiotek Zhuhai Limited \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RC28-E","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Public Offering","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Retinal Pigment Epithelial Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lineage Cell Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Raymon Pharmaceuticals Company, Ltd.","sponsor":"WuXi Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RMP-A03","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Suzhou Raymon Pharmaceuticals Company, Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Raymon Pharmaceuticals Company, Ltd. \/ WuXi Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Raymon Pharmaceuticals Company, Ltd. \/ WuXi Clinical"},{"orgOrder":0,"company":"SCAI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SCAI-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"SCAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCAI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SCAI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sacsh","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCH-1","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sacsh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sacsh \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sacsh \/ Undisclosed"},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Sclerfix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Patch","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Sunhawk Vision Biotech, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunhawk Vision Biotech, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunhawk Vision Biotech, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunhawk Vision Biotech, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sunhawk Vision Biotech, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sunhawk Vision Biotech, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunhawk Vision Biotech, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunhawk Vision Biotech, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Dreamhawk Vision Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHJ002","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Dreamhawk Vision Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dreamhawk Vision Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dreamhawk Vision Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"ActualEyes","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STN1010904","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ ActualEyes","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ ActualEyes"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STN1013600","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"STSP-0902","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"STSP-0902","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Synletis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SYL1801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Synletis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synletis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synletis \/ Undisclosed"},{"orgOrder":0,"company":"Sylentis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SYL1801","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sylentis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sylentis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sylentis \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"T4090","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Kukje Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TFC-003","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kukje Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kukje Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kukje Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BioTissue Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TTAX03","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"BioTissue Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioTissue Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioTissue Holdings \/ Undisclosed"},{"orgOrder":0,"company":"TissueTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TTBT01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"TissueTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TissueTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TissueTech \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VSJ-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VSJ-110","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vantage Biosciences","sponsor":"Vantage Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vantage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vantage Biosciences \/ Vantage Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Vantage Biosciences \/ Vantage Biosciences"},{"orgOrder":0,"company":"Vantage Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VX-01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Vantage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vantage Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vantage Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZKY001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Zhaoke Ophthalmology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhaoke Ophthalmology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhaoke Ophthalmology \/ Undisclosed"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IBE-814","moa":"Unknown","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ripple Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ripple Therapeutics \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Ripple Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SAF312","moa":"Vanilloid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanford University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"||Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Axitinib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clearside Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyoto Drug Discovery & Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KUS121","moa":"VCP\/p97","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyoto Drug Discovery & Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyoto Drug Discovery & Development \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyoto Drug Discovery & Development \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efdamrofusp Alfa","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IBI302","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sierra Eye Associates","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sierra Eye Associates","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sierra Eye Associates \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"Sierra Eye Associates \/ Regenxbio"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.75,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Regenxbio","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clearside Biomedical \/ Regenxbio","highestDevelopmentStatusID":"8","companyTruncated":"Clearside Biomedical \/ Regenxbio"},{"orgOrder":0,"company":"Regenxbio","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":1.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":1.75,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ AbbVie Inc"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regenxbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"RGX-314","moa":"VEGF receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KHK4951","moa":"VEGF1 receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADVM-022","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"ADVM-022","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Ixoberogene Soroparvovec","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adverum Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SB11","moa":"VEGF-A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-150","moa":"VEGF-A\/VEGF-B\/VEGF-C\/PlGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"4D-150","moa":"VEGF-A\/VEGF-B\/VEGF-C\/PlGF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"4D Molecular Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OcuTerra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nesvategrast","moa":"?v?3","graph1":"Ophthalmology","graph2":"Phase II","graph3":"OcuTerra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuTerra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OcuTerra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"}]

Find Ophthalmology Drugs in Phase II Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : EG-301 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 27, 2021

                          Lead Product(s) : EG-301

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Details : RGX-314 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 06, 2021

                          Lead Product(s) : RGX-314

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          03

                          Details : ABBV-RGX-314 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Retinopathy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 28, 2020

                          Lead Product(s) : ABBV-RGX-314

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Regenxbio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          04

                          Details : RGX-314 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Wet Macular Degeneration.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          August 17, 2020

                          Lead Product(s) : RGX-314

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : ZKY001 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Corneal Epithelial Defect.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 13, 2025

                          Lead Product(s) : ZKY001

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : CT1812 (zervimesine) is a sigma-2 receptor binder, being investigated as a potential oral treatment for adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : CT1812

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : BI 1584862, a phospholipid modulator developed by Boehringer Ingelheim, is an investigational compound with the potential to be a first-in-class oral treatment for Geographic Atrophy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 06, 2025

                          Lead Product(s) : BI 1584862

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : UBX1325 (foselutoclax) is a novel BCL-xL inhibitor, small molecule drug candidate, which is being evaluated for the treatment of diabetic macular edema.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 05, 2025

                          Lead Product(s) : Foselutoclax,Aflibercept

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : OK-101 (urcosimod) is a novel, non-opioid therapeutic candidate, is designed to target and alleviate the debilitating pain associated with corneal nerve damage.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : OK-101 (urcosimod) is a novel, non-opioid therapeutic candidate, is designed to target and alleviate the debilitating pain associated with corneal nerve damage.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          April 30, 2025

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank